Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23051
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPectasides, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorGogou, L.en
dc.contributor.authorAntoniou, F.en
dc.contributor.authorNicolaides, C.en
dc.contributor.authorTsikalakis, D.en
dc.date.accessioned2015-11-24T19:30:15Z-
dc.date.available2015-11-24T19:30:15Z-
dc.identifier.issn0277-3732-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23051-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntigens, Neoplasm/blooden
dc.subject*Antigens, Tumor-Associated, Carbohydrateen
dc.subjectBreast Neoplasms/*diagnosis/mortality/pathologyen
dc.subjectCarcinoembryonic Antigen/blooden
dc.subjectCarcinoma/*diagnosis/mortality/pathology/secondaryen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectMucin-1/blooden
dc.subjectPredictive Value of Testsen
dc.subjectSensitivity and Specificityen
dc.subjectSurvival Rateen
dc.subjectTissue Polypeptide Antigen/blooden
dc.subjectTumor Markers, Biological/*blooden
dc.titleClinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patientsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8823487-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1996-
heal.abstractA total of 209 postsurgical breast cancer patients were prospectively monitored with simultaneous serum level estimations of CA 15,3, mucin-like carcinoma-associated antigen (MCA), tumor polypeptide antigen (TPA), and carcinoembryonic antigen (CEA); 141 (67.5%) were free of recurrence and 68 (32.5%) developed metastases during the follow-up. The mean values of tested tumor markers differed significantly in those with progressive disease compared with those free of disease recurrence. The sensitivity of tumor markers were CA 15-3, 68.2%; CEA, 34.1%; MCA, 72.7%; and TPA, 72.7%. The combination of CA 15-3 with TPA or MCA with TPA showed a trend for improved sensitivity of both markers (p = 0.06), with no specific loss of specificity (p = 0.11). The addition of CEA to CA 15-3 or MCA does not provide additional information for clinical evaluation. Patients with elevated tumor marker determinations had significantly shorter survival than those with values within the normal range. Two serial, progressively increasing values of tumor markers during the follow-up strongly predict recurrence. This study indicates that the comeasurement of CA 15-3 with TPA or MCA with TPA is justifiable in monitoring breast cancer patients postoperatively.en
heal.journalNameAm J Clin Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons